94 related articles for article (PubMed ID: 20089400)
1. Synthesis and discovery of 2,3-dihydro-3,8-diphenylbenzo[1,4]oxazines as a novel class of potent cholesteryl ester transfer protein inhibitors.
Wang A; Prouty CP; Pelton PD; Yong M; Demarest KT; Murray WV; Kuo GH
Bioorg Med Chem Lett; 2010 Feb; 20(4):1432-5. PubMed ID: 20089400
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological evaluation of (2R,alphaS)-3,4-dihydro-2-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-5-[3-(trifluoromethoxy)-phenyl]-alpha-(trifluoromethyl)-1(2H)-quinolineethanol as potent and orally active cholesteryl ester transfer protein inhibitor.
Kuo GH; Rano T; Pelton P; Demarest KT; Gibbs AC; Murray WV; Damiano BP; Connelly MA
J Med Chem; 2009 Mar; 52(6):1768-72. PubMed ID: 19236017
[TBL] [Abstract][Full Text] [Related]
3. Chromanol derivatives--a novel class of CETP inhibitors.
Vakalopoulos A; Schmeck C; Thutewohl M; Li V; Bischoff H; Lustig K; Weber O; Paulsen H; Elias H
Bioorg Med Chem Lett; 2011 Jan; 21(1):488-91. PubMed ID: 21084191
[TBL] [Abstract][Full Text] [Related]
4. Tetrazole and ester substituted tetrahydoquinoxalines as potent cholesteryl ester transfer protein inhibitors.
Eary CT; Jones ZS; Groneberg RD; Burgess LE; Mareska DA; Drew MD; Blake JF; Laird ER; Balachari D; O'Sullivan M; Allen A; Marsh V
Bioorg Med Chem Lett; 2007 May; 17(9):2608-13. PubMed ID: 17331716
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of potent inhibitors of cholesteryl ester transfer protein (CETP) exploiting a 1,2,3,4-tetrahydroquinoline platform.
Rano TA; Sieber-McMaster E; Pelton PD; Yang M; Demarest KT; Kuo GH
Bioorg Med Chem Lett; 2009 May; 19(9):2456-60. PubMed ID: 19339179
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel benzoxazinones as potent and orally active long chain fatty acid elongase 6 inhibitors.
Mizutani T; Ishikawa S; Nagase T; Takahashi H; Fujimura T; Sasaki T; Nagumo A; Shimamura K; Miyamoto Y; Kitazawa H; Kanesaka M; Yoshimoto R; Aragane K; Tokita S; Sato N
J Med Chem; 2009 Nov; 52(22):7289-300. PubMed ID: 19883081
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a simple picomolar inhibitor of cholesteryl ester transfer protein.
Reinhard EJ; Wang JL; Durley RC; Fobian YM; Grapperhaus ML; Hickory BS; Massa MA; Norton MB; Promo MA; Tollefson MB; Vernier WF; Connolly DT; Witherbee BJ; Melton MA; Regina KJ; Smith ME; Sikorski JA
J Med Chem; 2003 May; 46(11):2152-68. PubMed ID: 12747787
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of new tetrahydroquinolines derivatives as CETP inhibitors.
Escribano A; Mateo AI; Martin de la Nava EM; Mayhugh DR; Cockerham SL; Beyer TP; Schmidt RJ; Cao G; Zhang Y; Jones TM; Borel AG; Sweetana SA; Cannady EA; Mantlo NB
Bioorg Med Chem Lett; 2012 Jun; 22(11):3671-5. PubMed ID: 22543028
[TBL] [Abstract][Full Text] [Related]
9. Diphenylpyridylethanamine (DPPE) derivatives as cholesteryl ester transfer protein (CETP) inhibitors.
Harikrishnan LS; Finlay HJ; Qiao JX; Kamau MG; Jiang J; Wang TC; Li J; Cooper CB; Poss MA; Adam LP; Taylor DS; Chen AY; Yin X; Sleph PG; Yang RZ; Sitkoff DF; Galella MA; Nirschl DS; Van Kirk K; Miller AV; Huang CS; Chang M; Chen XQ; Salvati ME; Wexler RR; Lawrence RM
J Med Chem; 2012 Jul; 55(13):6162-75. PubMed ID: 22650305
[TBL] [Abstract][Full Text] [Related]
10. Novel tetrahydrochinoline derived CETP inhibitors.
Schmeck C; Gielen-Haertwig H; Vakalopoulos A; Bischoff H; Li V; Wirtz G; Weber O
Bioorg Med Chem Lett; 2010 Mar; 20(5):1740-3. PubMed ID: 20137927
[TBL] [Abstract][Full Text] [Related]
11. 2-Arylbenzoxazoles as CETP inhibitors: raising HDL-C in cynoCETP transgenic mice.
Kallashi F; Kim D; Kowalchick J; Park YJ; Hunt JA; Ali A; Smith CJ; Hammond ML; Pivnichny JV; Tong X; Xu SS; Anderson MS; Chen Y; Eveland SS; Guo Q; Hyland SA; Milot DP; Cumiskey AM; Latham M; Peterson LB; Rosa R; Sparrow CP; Wright SD; Sinclair PJ
Bioorg Med Chem Lett; 2011 Jan; 21(1):558-61. PubMed ID: 21094047
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and structure-activity-relationship of 1,5-tetrahydronaphthyridines as CETP inhibitors.
Fernandez MC; Escribano A; Mateo AI; Parthasarathy S; Martin de la Nava EM; Wang X; Cockerham SL; Beyer TP; Schmidt RJ; Cao G; Zhang Y; Jones TM; Borel A; Sweetana SA; Cannady EA; Stephenson G; Frank S; Mantlo NB
Bioorg Med Chem Lett; 2012 May; 22(9):3056-62. PubMed ID: 22497761
[TBL] [Abstract][Full Text] [Related]
13. 2-(4-carbonylphenyl)benzoxazole inhibitors of CETP: scaffold design and advancement in HDLc-raising efficacy.
Sweis RF; Hunt JA; Kallashi F; Hammond ML; Chen Y; Eveland SS; Guo Q; Hyland SA; Milot DP; Cumiskey AM; Latham M; Rosa R; Peterson L; Sparrow CP; Wright SD; Anderson MS; Sinclair PJ
Bioorg Med Chem Lett; 2011 Mar; 21(6):1890-5. PubMed ID: 21147531
[TBL] [Abstract][Full Text] [Related]
14. Design of a novel class of biphenyl CETP inhibitors.
Lu Z; Napolitano JB; Theberge A; Ali A; Hammond ML; Tan E; Tong X; Xu SS; Latham MJ; Peterson LB; Anderson MS; Eveland SS; Guo Q; Hyland SA; Milot DP; Chen Y; Sparrow CP; Wright SD; Sinclair PJ
Bioorg Med Chem Lett; 2010 Dec; 20(24):7469-72. PubMed ID: 21041082
[TBL] [Abstract][Full Text] [Related]
15. Triphenylethanamine Derivatives as Cholesteryl Ester Transfer Protein Inhibitors: Discovery of N-[(1R)-1-(3-Cyclopropoxy-4-fluorophenyl)-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-2-phenylethyl]-4-fluoro-3-(trifluoromethyl)benzamide (BMS-795311).
Qiao JX; Wang TC; Adam LP; Chen AY; Taylor DS; Yang RZ; Zhuang S; Sleph PG; Li JP; Li D; Yin X; Chang M; Chen XQ; Shen H; Li J; Smith D; Wu DR; Leith L; Harikrishnan LS; Kamau MG; Miller MM; Bilder D; Rampulla R; Li YX; Xu C; Lawrence RM; Poss MA; Levesque P; Gordon DA; Huang CS; Finlay HJ; Wexler RR; Salvati ME
J Med Chem; 2015 Nov; 58(22):9010-26. PubMed ID: 26524347
[TBL] [Abstract][Full Text] [Related]
16. Thyroid hormone increases plasma cholesteryl ester transfer protein activity and plasma high-density lipoprotein removal rate in transgenic mice.
Berti JA; Amaral ME; Boschero AC; Nunes VS; Harada LM; Castilho LN; Oliveira HC
Metabolism; 2001 May; 50(5):530-6. PubMed ID: 11319713
[TBL] [Abstract][Full Text] [Related]
17. Cholesteryl ester transfer protein promotes the formation of cholesterol-rich remnant like lipoprotein particles in human plasma.
Okamoto H; Miyai A; Sasase T; Furukawa N; Matsushita M; Nakano T; Nakajima K
Clin Chim Acta; 2007 Jan; 375(1-2):92-8. PubMed ID: 16859664
[TBL] [Abstract][Full Text] [Related]
18. Biphenyl-substituted oxazolidinones as cholesteryl ester transfer protein inhibitors: modifications of the oxazolidinone ring leading to the discovery of anacetrapib.
Smith CJ; Ali A; Hammond ML; Li H; Lu Z; Napolitano J; Taylor GE; Thompson CF; Anderson MS; Chen Y; Eveland SS; Guo Q; Hyland SA; Milot DP; Sparrow CP; Wright SD; Cumiskey AM; Latham M; Peterson LB; Rosa R; Pivnichny JV; Tong X; Xu SS; Sinclair PJ
J Med Chem; 2011 Jul; 54(13):4880-95. PubMed ID: 21682257
[TBL] [Abstract][Full Text] [Related]
19. Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis.
La DS; Belzile J; Bready JV; Coxon A; DeMelfi T; Doerr N; Estrada J; Flynn JC; Flynn SR; Graceffa RF; Harriman SP; Larrow JF; Long AM; Martin MW; Morrison MJ; Patel VF; Roveto PM; Wang L; Weiss MM; Whittington DA; Teffera Y; Zhao Z; Polverino AJ; Harmange JC
J Med Chem; 2008 Mar; 51(6):1695-705. PubMed ID: 18311900
[TBL] [Abstract][Full Text] [Related]
20. 2D Quantitative structure-activity relationship studies on a series of cholesteryl ester transfer protein inhibitors.
Castilho MS; Guido RV; Andricopulo AD
Bioorg Med Chem; 2007 Sep; 15(18):6242-52. PubMed ID: 17604633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
